Bevacizumab is a monoclonal antibody and, besides its well-known inhibitory effect on tumor angiogenesis, attenuates VEGFA-mediated signaling in complicated lymphatic anomalies (CLAs) (13, 14). This evidence concerns the gene VEGFA and neoplasm.